Cargando…
Integrated genetic and clinical prognostic factors for aggressive adult T-cell leukemia/lymphoma
The prognosis of aggressive adult T-cell leukemia/lymphoma (ATL) is poor, and allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative treatment. In order to identify favorable prognostic patients after intensive chemotherapy, and who therefore might not require upfront allo-HSCT...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Fondazione Ferrata Storti
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10388278/ https://www.ncbi.nlm.nih.gov/pubmed/36794502 http://dx.doi.org/10.3324/haematol.2022.281510 |
_version_ | 1785082078682939392 |
---|---|
author | Kameda, Takuro Kataoka, Keisuke Kamiunten, Ayako Hidaka, Michihiro Miyoshi, Hiroaki Nakano, Nobuaki Nosaka, Kisato Yoshimitsu, Makoto Yasunaga, Jun-ichirou Kogure, Yasunori Shide, Kotaro Miyahara, Masaharu Sakamoto, Takashi Akizuki, Keiichi Hidaka, Tomonori Kubuki, Yoko Koya, Junji Kawano, Noriaki Yamashita, Kiyoshi Kawano, Hiroshi Toyama, Takanori Maeda, Kouichi Marutsuka, Kosuke Imaizumi, Yoshitaka Kato, Koji Sugio, Takeshi Tokunaga, Masahito Tashiro, Yukie Takaori-Kondo, Akifumi Miyazaki, Yasushi Akashi, Koichi Ishitsuka, Kenji Matsuoka, Masao Ohshima, Koichi Watanabe, Toshiki Kitanaka, Akira Utsunomiya, Atae Ogawa, Seishi Shimoda, Kazuya |
author_facet | Kameda, Takuro Kataoka, Keisuke Kamiunten, Ayako Hidaka, Michihiro Miyoshi, Hiroaki Nakano, Nobuaki Nosaka, Kisato Yoshimitsu, Makoto Yasunaga, Jun-ichirou Kogure, Yasunori Shide, Kotaro Miyahara, Masaharu Sakamoto, Takashi Akizuki, Keiichi Hidaka, Tomonori Kubuki, Yoko Koya, Junji Kawano, Noriaki Yamashita, Kiyoshi Kawano, Hiroshi Toyama, Takanori Maeda, Kouichi Marutsuka, Kosuke Imaizumi, Yoshitaka Kato, Koji Sugio, Takeshi Tokunaga, Masahito Tashiro, Yukie Takaori-Kondo, Akifumi Miyazaki, Yasushi Akashi, Koichi Ishitsuka, Kenji Matsuoka, Masao Ohshima, Koichi Watanabe, Toshiki Kitanaka, Akira Utsunomiya, Atae Ogawa, Seishi Shimoda, Kazuya |
author_sort | Kameda, Takuro |
collection | PubMed |
description | The prognosis of aggressive adult T-cell leukemia/lymphoma (ATL) is poor, and allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative treatment. In order to identify favorable prognostic patients after intensive chemotherapy, and who therefore might not require upfront allo-HSCT, we aimed to improve risk stratification of aggressive ATL patients aged <70 years. The clinical risk factors and genetic mutations were incorporated into risk modeling for overall survival (OS). We generated the m7-ATLPI, a clinicogenetic risk model for OS, that included the ATL prognostic index (PI) (ATL-PI) risk category, and non-silent mutations in seven genes, namely TP53, IRF4, RHOA, PRKCB, CARD11, CCR7, and GATA3. In the training cohort of 99 patients, the m7-ATLPI identified a low-, intermediate-, and high-risk group with 2-year OS of 100%, 43%, and 19%, respectively (hazard ratio [HR] =5.46; P<0.0001). The m7-ATLPI achieved superior risk stratification compared to the current ATL-PI (C-index 0.92 vs. 0.85, respectively). In the validation cohort of 84 patients, the m7-ATLPI defined low-, intermediate-, and high-risk groups with a 2-year OS of 81%, 30%, and 0%, respectively (HR=2.33; P=0.0094), and the model again outperformed the ATL-PI (C-index 0.72 vs. 0.70, respectively). The simplified m7-ATLPI, which is easier to use in clinical practice, achieved superior risk stratification compared to the ATL-PI, as did the original m7-ATLPI; the simplified version was calculated by summing the following: high-risk ATL-PI category (+10), low-risk ATL-PI category (-4), and non-silent mutations in TP53 (+4), IRF4 (+3), RHOA (+1), PRKCB (+1), CARD11 (+0.5), CCR7 (-2), and GATA3 (-3). |
format | Online Article Text |
id | pubmed-10388278 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Fondazione Ferrata Storti |
record_format | MEDLINE/PubMed |
spelling | pubmed-103882782023-08-01 Integrated genetic and clinical prognostic factors for aggressive adult T-cell leukemia/lymphoma Kameda, Takuro Kataoka, Keisuke Kamiunten, Ayako Hidaka, Michihiro Miyoshi, Hiroaki Nakano, Nobuaki Nosaka, Kisato Yoshimitsu, Makoto Yasunaga, Jun-ichirou Kogure, Yasunori Shide, Kotaro Miyahara, Masaharu Sakamoto, Takashi Akizuki, Keiichi Hidaka, Tomonori Kubuki, Yoko Koya, Junji Kawano, Noriaki Yamashita, Kiyoshi Kawano, Hiroshi Toyama, Takanori Maeda, Kouichi Marutsuka, Kosuke Imaizumi, Yoshitaka Kato, Koji Sugio, Takeshi Tokunaga, Masahito Tashiro, Yukie Takaori-Kondo, Akifumi Miyazaki, Yasushi Akashi, Koichi Ishitsuka, Kenji Matsuoka, Masao Ohshima, Koichi Watanabe, Toshiki Kitanaka, Akira Utsunomiya, Atae Ogawa, Seishi Shimoda, Kazuya Haematologica Article - Non-Hodgkin Lymphoma The prognosis of aggressive adult T-cell leukemia/lymphoma (ATL) is poor, and allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative treatment. In order to identify favorable prognostic patients after intensive chemotherapy, and who therefore might not require upfront allo-HSCT, we aimed to improve risk stratification of aggressive ATL patients aged <70 years. The clinical risk factors and genetic mutations were incorporated into risk modeling for overall survival (OS). We generated the m7-ATLPI, a clinicogenetic risk model for OS, that included the ATL prognostic index (PI) (ATL-PI) risk category, and non-silent mutations in seven genes, namely TP53, IRF4, RHOA, PRKCB, CARD11, CCR7, and GATA3. In the training cohort of 99 patients, the m7-ATLPI identified a low-, intermediate-, and high-risk group with 2-year OS of 100%, 43%, and 19%, respectively (hazard ratio [HR] =5.46; P<0.0001). The m7-ATLPI achieved superior risk stratification compared to the current ATL-PI (C-index 0.92 vs. 0.85, respectively). In the validation cohort of 84 patients, the m7-ATLPI defined low-, intermediate-, and high-risk groups with a 2-year OS of 81%, 30%, and 0%, respectively (HR=2.33; P=0.0094), and the model again outperformed the ATL-PI (C-index 0.72 vs. 0.70, respectively). The simplified m7-ATLPI, which is easier to use in clinical practice, achieved superior risk stratification compared to the ATL-PI, as did the original m7-ATLPI; the simplified version was calculated by summing the following: high-risk ATL-PI category (+10), low-risk ATL-PI category (-4), and non-silent mutations in TP53 (+4), IRF4 (+3), RHOA (+1), PRKCB (+1), CARD11 (+0.5), CCR7 (-2), and GATA3 (-3). Fondazione Ferrata Storti 2023-02-16 /pmc/articles/PMC10388278/ /pubmed/36794502 http://dx.doi.org/10.3324/haematol.2022.281510 Text en Copyright© 2023 Ferrata Storti Foundation https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. |
spellingShingle | Article - Non-Hodgkin Lymphoma Kameda, Takuro Kataoka, Keisuke Kamiunten, Ayako Hidaka, Michihiro Miyoshi, Hiroaki Nakano, Nobuaki Nosaka, Kisato Yoshimitsu, Makoto Yasunaga, Jun-ichirou Kogure, Yasunori Shide, Kotaro Miyahara, Masaharu Sakamoto, Takashi Akizuki, Keiichi Hidaka, Tomonori Kubuki, Yoko Koya, Junji Kawano, Noriaki Yamashita, Kiyoshi Kawano, Hiroshi Toyama, Takanori Maeda, Kouichi Marutsuka, Kosuke Imaizumi, Yoshitaka Kato, Koji Sugio, Takeshi Tokunaga, Masahito Tashiro, Yukie Takaori-Kondo, Akifumi Miyazaki, Yasushi Akashi, Koichi Ishitsuka, Kenji Matsuoka, Masao Ohshima, Koichi Watanabe, Toshiki Kitanaka, Akira Utsunomiya, Atae Ogawa, Seishi Shimoda, Kazuya Integrated genetic and clinical prognostic factors for aggressive adult T-cell leukemia/lymphoma |
title | Integrated genetic and clinical prognostic factors for aggressive adult T-cell leukemia/lymphoma |
title_full | Integrated genetic and clinical prognostic factors for aggressive adult T-cell leukemia/lymphoma |
title_fullStr | Integrated genetic and clinical prognostic factors for aggressive adult T-cell leukemia/lymphoma |
title_full_unstemmed | Integrated genetic and clinical prognostic factors for aggressive adult T-cell leukemia/lymphoma |
title_short | Integrated genetic and clinical prognostic factors for aggressive adult T-cell leukemia/lymphoma |
title_sort | integrated genetic and clinical prognostic factors for aggressive adult t-cell leukemia/lymphoma |
topic | Article - Non-Hodgkin Lymphoma |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10388278/ https://www.ncbi.nlm.nih.gov/pubmed/36794502 http://dx.doi.org/10.3324/haematol.2022.281510 |
work_keys_str_mv | AT kamedatakuro integratedgeneticandclinicalprognosticfactorsforaggressiveadulttcellleukemialymphoma AT kataokakeisuke integratedgeneticandclinicalprognosticfactorsforaggressiveadulttcellleukemialymphoma AT kamiuntenayako integratedgeneticandclinicalprognosticfactorsforaggressiveadulttcellleukemialymphoma AT hidakamichihiro integratedgeneticandclinicalprognosticfactorsforaggressiveadulttcellleukemialymphoma AT miyoshihiroaki integratedgeneticandclinicalprognosticfactorsforaggressiveadulttcellleukemialymphoma AT nakanonobuaki integratedgeneticandclinicalprognosticfactorsforaggressiveadulttcellleukemialymphoma AT nosakakisato integratedgeneticandclinicalprognosticfactorsforaggressiveadulttcellleukemialymphoma AT yoshimitsumakoto integratedgeneticandclinicalprognosticfactorsforaggressiveadulttcellleukemialymphoma AT yasunagajunichirou integratedgeneticandclinicalprognosticfactorsforaggressiveadulttcellleukemialymphoma AT kogureyasunori integratedgeneticandclinicalprognosticfactorsforaggressiveadulttcellleukemialymphoma AT shidekotaro integratedgeneticandclinicalprognosticfactorsforaggressiveadulttcellleukemialymphoma AT miyaharamasaharu integratedgeneticandclinicalprognosticfactorsforaggressiveadulttcellleukemialymphoma AT sakamototakashi integratedgeneticandclinicalprognosticfactorsforaggressiveadulttcellleukemialymphoma AT akizukikeiichi integratedgeneticandclinicalprognosticfactorsforaggressiveadulttcellleukemialymphoma AT hidakatomonori integratedgeneticandclinicalprognosticfactorsforaggressiveadulttcellleukemialymphoma AT kubukiyoko integratedgeneticandclinicalprognosticfactorsforaggressiveadulttcellleukemialymphoma AT koyajunji integratedgeneticandclinicalprognosticfactorsforaggressiveadulttcellleukemialymphoma AT kawanonoriaki integratedgeneticandclinicalprognosticfactorsforaggressiveadulttcellleukemialymphoma AT yamashitakiyoshi integratedgeneticandclinicalprognosticfactorsforaggressiveadulttcellleukemialymphoma AT kawanohiroshi integratedgeneticandclinicalprognosticfactorsforaggressiveadulttcellleukemialymphoma AT toyamatakanori integratedgeneticandclinicalprognosticfactorsforaggressiveadulttcellleukemialymphoma AT maedakouichi integratedgeneticandclinicalprognosticfactorsforaggressiveadulttcellleukemialymphoma AT marutsukakosuke integratedgeneticandclinicalprognosticfactorsforaggressiveadulttcellleukemialymphoma AT imaizumiyoshitaka integratedgeneticandclinicalprognosticfactorsforaggressiveadulttcellleukemialymphoma AT katokoji integratedgeneticandclinicalprognosticfactorsforaggressiveadulttcellleukemialymphoma AT sugiotakeshi integratedgeneticandclinicalprognosticfactorsforaggressiveadulttcellleukemialymphoma AT tokunagamasahito integratedgeneticandclinicalprognosticfactorsforaggressiveadulttcellleukemialymphoma AT tashiroyukie integratedgeneticandclinicalprognosticfactorsforaggressiveadulttcellleukemialymphoma AT takaorikondoakifumi integratedgeneticandclinicalprognosticfactorsforaggressiveadulttcellleukemialymphoma AT miyazakiyasushi integratedgeneticandclinicalprognosticfactorsforaggressiveadulttcellleukemialymphoma AT akashikoichi integratedgeneticandclinicalprognosticfactorsforaggressiveadulttcellleukemialymphoma AT ishitsukakenji integratedgeneticandclinicalprognosticfactorsforaggressiveadulttcellleukemialymphoma AT matsuokamasao integratedgeneticandclinicalprognosticfactorsforaggressiveadulttcellleukemialymphoma AT ohshimakoichi integratedgeneticandclinicalprognosticfactorsforaggressiveadulttcellleukemialymphoma AT watanabetoshiki integratedgeneticandclinicalprognosticfactorsforaggressiveadulttcellleukemialymphoma AT kitanakaakira integratedgeneticandclinicalprognosticfactorsforaggressiveadulttcellleukemialymphoma AT utsunomiyaatae integratedgeneticandclinicalprognosticfactorsforaggressiveadulttcellleukemialymphoma AT ogawaseishi integratedgeneticandclinicalprognosticfactorsforaggressiveadulttcellleukemialymphoma AT shimodakazuya integratedgeneticandclinicalprognosticfactorsforaggressiveadulttcellleukemialymphoma |